Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Intratumor heterogeneity reflects clinical disease course

Nature Cancer volume 1, pages 3–6 (2020)Cite this article

Subjects

Intratumoral genetic heterogeneity of driver somatic mutations is present in a variety of tumor types, yet the extent of heterogeneity is variable. We propose that this variation is a reflection of the inherent biology of a given tumor type, representing the pace of metastatic dissemination and hence clinical disease course.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Evolutionary trajectories in solid tumors and relationship to clinical course.

References

  1. Greaves, M. Cancer Discov. 5, 806–820 (2015).

    Article  CAS  Google Scholar 

  2. Greaves, M. Nat. Rev. Cancer 7, 213–221 (2007).

    Article  CAS  Google Scholar 

  3. Gillies, R. J., Verduzco, D. & Gatenby, R. A. Nat. Rev. Cancer 12, 487–493 (2012).

    Article  CAS  Google Scholar 

  4. Williams, M. J. et al. Nat. Genet. 50, 895–903 (2018).

    Article  CAS  Google Scholar 

  5. Greaves, M. & Maley, C. C. Nature 481, 306–313 (2012).

    Article  CAS  Google Scholar 

  6. Turajlic, S. et al. Cell 173, 595–610 (2018).

    Article  CAS  Google Scholar 

  7. Makohon-Moore, A. P. et al. Nat. Genet. 49, 358–366 (2017).

    Article  CAS  Google Scholar 

  8. Maley, C. C. et al. Nat. Rev. Cancer 17, 605–619 (2017).

    Article  CAS  Google Scholar 

  9. Krabbe, L.-M., Bagrodia, A., Margulis, V. & Wood, C. Semin. Intervent. Radiol. 31, 27–32 (2014).

    Article  Google Scholar 

  10. Kleeff, J. et al. Nat. Rev. Dis. Primers 2, 16022 (2016).

    Article  Google Scholar 

  11. Winter, J. M. et al. Ann. Surg. Oncol. 19, 169–175 (2012).

    Article  Google Scholar 

  12. Turajlic, S. et al. Cell 173, 581–594 (2018).

    Article  CAS  Google Scholar 

  13. McDonald, O. G. O. G. et al. Nat. Genet. 49, 367–376 (2017).

    Article  CAS  Google Scholar 

  14. Gomez, K. et al. BMC Cancer 18, 85 (2018).

    Article  Google Scholar 

  15. Gundem, G. et al. Nature 520, 353–357 (2015).

    Article  CAS  Google Scholar 

  16. Kohutek, Z. A. et al. Cold Spring Harb. Mol. Case Stud. 3, a001701 (2017).

    Article  Google Scholar 

  17. Blakely, C. M. et al. Nat. Genet. 49, 1693–1704 (2017).

    Article  CAS  Google Scholar 

  18. Juric, D. et al. Nature 518, 240–244 (2015).

    Article  CAS  Google Scholar 

  19. Jamal-Hanjani, M. et al. N. Engl. J. Med. 376, 2109–2121 (2017).

    Article  CAS  Google Scholar 

  20. Kovac, M. et al. Nat. Commun. 6, 6336 (2015).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Research support by CA179991 and CA220508 to C.A.I.D., who also receives research support from Bristol-Myers Squibb. K.L. is supported by a UK Medical Research Council Skills Development Fellowship Award (grant reference number MR/P014712/1). C.S. is supported by the Francis Crick Institute that receives its core funding from Cancer Research UK (FC001169,FC001202), the UK Medical Research Council (FC001169, FC001202), and the Wellcome Trust (FC001169, FC001202) and from Cancer Research UK (TRACERx, PEACE and CRUK Cancer Immunotherapy Catalyst Network), the CRUK Lung Cancer Centre of Excellence, Stand Up 2 Cancer (SU2C), the Rosetrees Trust, NovoNordisk Foundation (ID16584) and the Breast Cancer Research Foundation (BCRF), European Research Council under the European Union’s Seventh Framework Programme (FP7/2007-2013)/ ERC grant agreement n°FP7 – 617844 (PROTEUS) and Marie Curie Network PloidyNet.

Author information

Authors and Affiliations

  1. David M. Rubenstein Center for Pancreatic Cancer Research, Department of Pathology, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Christine A. Iacobuzio-Donahue

  2. Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, Paul O’Gorman Building, London, UK

    Kevin Litchfield & Charles Swanton

  3. Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK

    Kevin Litchfield & Charles Swanton

Authors
  1. Christine A. Iacobuzio-Donahue
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kevin Litchfield
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Charles Swanton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Christine A. Iacobuzio-Donahue or Charles Swanton.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Iacobuzio-Donahue, C.A., Litchfield, K. & Swanton, C. Intratumor heterogeneity reflects clinical disease course. Nat Cancer 1, 3–6 (2020). https://doi.org/10.1038/s43018-019-0002-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43018-019-0002-1

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer